Clinical Trials Directory

Trials / Unknown

UnknownNCT04136470

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

Development of BioForte Technology for in Silico Identification of Valuable Genomic Features That Are Candidates for Microbiome-based Therapeutics and Diagnostics.

Status
Unknown
Phase
Study type
Observational
Enrollment
130 (estimated)
Sponsor
Ardigen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of the project is to develop and validate the BioForte technology. Its main functionality should be to in silico determine candidates for novel microbiome-based therapeutics and diagnostics. Key challenge to be solved using the technology is to detect the differences in gut microbiome between oncology patients who respond to immunotherapies and the ones who do not respond to this treatment. This technology employs machine learning methods to replace the laboratory procedure for finding valuable genomic features. Such features can be crucial to identify differences between the two populations (e.g. responders vs non-responders) to target specific strains. The samples and data collected in this clinical study will be used for clinical validation of BioForte technology. For all patients treated with immunotherapy, stool collection will be performed per patient (one stool collection before setting up immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies). Samples will be sequenced by long-read sequencing technology. In parallel, we will also collect samples of peripheral blood samples (PBMC) and biopsy (FFPE).

Conditions

Interventions

TypeNameDescription
BIOLOGICALCollection of stool, blood (PBMC) and biopsy (FFPE)Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).

Timeline

Start date
2019-04-01
Primary completion
2020-09-30
Completion
2021-03-31
First posted
2019-10-23
Last updated
2020-08-10

Locations

10 sites across 1 country: Poland

Source: ClinicalTrials.gov record NCT04136470. Inclusion in this directory is not an endorsement.

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics (NCT04136470) · Clinical Trials Directory